We also replicated the polygenic risk score association with β-amyloid (CSF β-amyloid1–42/β-amyloid1–40) and tau (CSF pTau217) in an independent cohort (BioFINDER-2), including cognitively unimpaired (N = 773) individuals and patients with mild cognitive impairment (N = 358), Alzheimer’s disease dementia (N = 286) or non-Alzheimer’s disease neurodegenerative diseases (N = 319). This evidence concerns the gene MAPT and Alzheimer disease.